Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Probiotics for Vascular Inflammation in Metabolic Syndrome (PROMISE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03719794
Recruitment Status : Recruiting
First Posted : October 25, 2018
Last Update Posted : October 25, 2018
Sponsor:
Collaborator:
Lallemand Health Solutions
Information provided by (Responsible Party):
Montreal Heart Institute

Brief Summary:
Subjects with metabolic syndrome are known to possess chronic low-level inflammation. Furthermore, such individuals are at risk of developing atherosclerosis in coronary and other vascular beds. In particular, subjects with metabolic syndrome, prediabetes and type II diabetes mellitus were shown to possess vascular inflammation in carotid atherosclerosis as demonstrated using FDG-PET. In the current pilot proposal, the investigators wish to study the impact of 3-month probiotic supplementation on vascular and systemic inflammation in subjects with metabolic syndrome in the context of a randomized, placebo-controlled, pilot trial.

Condition or disease Intervention/treatment Phase
Metabolic Syndrome Dietary Supplement: Probiotic supplement Dietary Supplement: Placebo supplement Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 24 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Prevention
Official Title: Probiotics for Vascular Inflammation in Metabolic Syndrome (PROMISE): a 12-Week Pilot Study, Randomized,Double-Blinded, Placebo-Controlled Trial
Actual Study Start Date : April 16, 2018
Estimated Primary Completion Date : April 2019
Estimated Study Completion Date : September 2019

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Active Comparator: Probiotics arm
The active comparator arm will be of a 12-week probiotic supplement regimen (one capsule daily, containing 20 x 109 CFU of Bifidobacterium animalis ssp. Lactis Lafti®B94 and Lactobacillus plantarum R1012)
Dietary Supplement: Probiotic supplement
Probiotic supplement once daily (xyz) for 12 weeks

Placebo Comparator: Placebo arm
The placebo comparator arm will be of a 12-week placebo supplement regimen.
Dietary Supplement: Placebo supplement
Placebo supplement once daily for 12 weeks




Primary Outcome Measures :
  1. The primary outcome is to evaluate the change on vascular inflammation (measured by FDG-PET), so as to test the hypothesis that probiotic treatment reduces vascular inflammation in comparison to placebo. [ Time Frame: At baseline and following 12 weeks of probiotic supplementation or placebo. ]
    PET-CT scan of the carotid arteries and ascending thoracic aorta will be performed 2 hours post I.V. The participant will be injected with 18F-FDG.


Secondary Outcome Measures :
  1. Mesure of High-sensitivity C-reactive protein (hs-CRP) a systemic inflammatory marker. [ Time Frame: At baseline and following 12 weeks of probiotic supplementation or placebo. ]
    Change with hs-CRP

  2. Mesure of Tumor necrosis factor alpha (TNF-α) a systemic inflammatory marker. [ Time Frame: At baseline and following 12 weeks of probiotic supplementation or placebo. ]
    Change with TNF-α

  3. Mesure of Matrix metallopeptidase 9 (MMP-9) [ Time Frame: At baseline and following 12 weeks of probiotic supplementation or placebo. ]
    Change with MMP-9

  4. Cognitive function at rest by a standard pen-paper battery test. [ Time Frame: At baseline and following 12 weeks of probiotic supplementation or placebo. ]
    Cognitive functions will be measured at rest with a pen-paper battery test by a neuropsychologist. The investigators will measure change of score to the cognitive tests.

  5. Intestinal microbiota community composition [ Time Frame: At baseline and following 12 weeks of probiotic supplementation or placebo. ]
    To evaluate the impact on intestinal microbiota community composition


Other Outcome Measures:
  1. Mesure of blood fasting glucose [ Time Frame: At baseline and following 12 weeks of probiotic supplementation or placebo. ]
    Change in fasting glucose

  2. Mesure of blood Serum lipids [ Time Frame: At baseline and following 12 weeks of probiotic supplementation or placebo. ]
    Change in serum lipids



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   50 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Male and female age > 50 years
  • Presence of MetS as defined according to recent updated criteria (13): Presence of at least three of five criteria, namely abdominal obesity (waist circumference cut-off) depending on the recently published ethnic-based variations (14), triglycerides > 1.70 mmol/l, decreased HDL-cholesterol (< 1.0 mmol/l in men and < 1.3 mmol/l in women), systolic blood pressure > 130 mmHg or diastolic blood pressure > 85 mmHg, and FPG > 5.6 mmol/l.
  • Willingness to complete questionnaires, records, and diaries associated with the study and to complete all clinic visits.
  • Willingness to discontinue consumption of fermented foods or probiotics (e.g. yoghourts, with live, active cultures or supplements).
  • Able to provide informed consent.

Exclusion Criteria:

  • Concurrent consumption of fermented foods or probiotics (e.g. yoghourts, with live, active cultures or supplements). Subjects will be eligible for participation, however, after a two-week washout period
  • Overt or documented vascular disease (coronary heart disease, cerebrovascular disease, or peripheral vascular disease).
  • Participants suffering from dementia (mini mental state examination) or depression (geriatric depression scale).
  • Concurrent statin therapy. (Statins have been shown to reduce vascular inflammation as measured by FDG-PET-see section 9.1).
  • Color blind
  • Concurrent antibiotic therapy. However, screened participants would be eligible to participate two weeks after completing their course of antibiotics (wash-out period).
  • Known to be pregnant or breast-feeding or planning on becoming pregnant in the next 18 months.
  • Women of childbearing potential not using effective contraception. Acceptable methods of birth control includes:
  • Hormonal contraceptives including combined oral contraceptives, hormone birth control patch, vaginal contraceptive ring, injectable contraceptives, or hormonal implants;
  • Intrauterine devices (IUD) or Intrauterine system (IUS);
  • Tubal ligation;
  • Vasectomy of partner;
  • Double barrier method (use of physical barrier by both partners, e.g. male condom and diaphragm, male condom and cervical cap).
  • Positive pregnancy test in women of childbearing potential.
  • Allergy to milk, soy, or yeast.
  • Use of another investigational product within 3 months of the screening visit.
  • Claustrophobia
  • Patient with pacemaker
  • Patient with BMI greater than 40 kg/m2
  • Immune disorder.
  • Drug and alcohol abuse
  • Current use of NSAIDs
  • Liver and kidney disorders
  • Bleeding/blood disorder

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03719794


Contacts
Layout table for location contacts
Contact: Lalonge 514-374-1480 ext 4259 julie.lalonge@icm-mhi.org
Contact: Anil Nigam 514-376-3330 ext 4033 anil.nigam@icm-mhi.org

Locations
Layout table for location information
Canada, Quebec
Cardiovascular Prevention and Rehabilitation Center Recruiting
Montreal, Quebec, Canada, H1T 1N6
Contact: Julie Lalongé    5143741480 ext 4259    julie.lalonge@icm-mhi.org   
Principal Investigator: Anil Nigam, MD         
Sponsors and Collaborators
Montreal Heart Institute
Lallemand Health Solutions
Investigators
Layout table for investigator information
Principal Investigator: Anil Nigam, MD Montreal Heart Institute

Layout table for additonal information
Responsible Party: Montreal Heart Institute
ClinicalTrials.gov Identifier: NCT03719794     History of Changes
Other Study ID Numbers: 2016-2038
First Posted: October 25, 2018    Key Record Dates
Last Update Posted: October 25, 2018
Last Verified: October 2018

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Layout table for MeSH terms
Syndrome
Inflammation
Metabolic Syndrome
Disease
Pathologic Processes
Insulin Resistance
Hyperinsulinism
Glucose Metabolism Disorders
Metabolic Diseases